Daiken Biomedical Co., Ltd. (7780) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daiken Biomedical Co., Ltd. (7780:TWSE), powered by AI.

Current Price
$185.00
P/E Ratio
76.2
Market Cap
8.1B
Sector
Consumer Defensive
What is the Daiken Biomedical Co., Ltd. stock price forecast?

Daiken Biomedical Co., Ltd. is currently trading at $185.00. View real-time AI analysis on Alpha Lenz.

What is Daiken Biomedical Co., Ltd. insider trading activity?

View the latest insider trading data for Daiken Biomedical Co., Ltd. on Alpha Lenz.

What is Daiken Biomedical Co., Ltd.'s P/E ratio?

Daiken Biomedical Co., Ltd.'s P/E ratio is 76.2.

Daiken Biomedical Co., Ltd.

TWSE · 7780
NT$185.00+0.00(+0.00%)
Ask about Daiken Biomedical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Daiken Biomedical Co., Ltd. trades at a P/E of 76.2 (premium valuation) with solid ROE of 13.7%.

Ask for details

Company Overview

Daiken Biomedical Co., Ltd. is a Taiwan-based company specializing in the research, development, and sales of health food and nutritional supplements. Established in 2018, the company delivers a wide array of products including fish oil soft capsules, lutein for eye health, maca supplements, bitter melon peptide cinnamon capsules, probiotics for women, sesamin for sleep, and dietary fiber powders. Daiken Biomedical emphasizes evidence-based product development, leveraging an international biomedical research team comprising experts from the United States, Japan, and Taiwan to ensure rigorous safety and efficacy standards. Its offerings are marketed primarily within Taiwan, both through online channels such as momo, Shopee, and PChome, and in physical retail outlets like Watsons and FamilyMart. The company plays a prominent role in Taiwan’s consumer defensive sector, serving the growing demand for lifestyle-oriented, scientifically substantiated health products. Daiken Biomedical is notable for integrating global research perspectives and maintaining direct relationships with end consumers, reflecting its commitment to both product quality and customer trust.

SectorConsumer Defensive
IndustryPackaged Foods
0

Company Statistics

FY 2024

Profile

NT$8.12BMarket Cap
NT$1.36BRevenue
0.00Shares Out
0Employees

Margins

62.85%Gross
11.06%EBITDA
11.00%Operating
10.25%Pre-Tax
7.82%Net

Valuation

76.16P/E
6.21P/B
5.96EV/Sales
46.33EV/EBITDA
167.26P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

9.34%ROA
13.71%ROE
12.76%ROIC

Financial Health

NT$1.14BCash & Cash Equivalents
NT$-908.91MNet Debt
17.66%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daiken Biomedical Co., Ltd. (ticker: 7780) is a company listed on TWSE in the Consumer Defensive sector (Packaged Foods). Market cap is $8.1B.

The current price is 185 with a P/E ratio of 76.16x and P/B of 6.21x.

ROE is 13.71% and operating margin is 11.00%. Annual revenue is $1.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daiken Biomedical Co., Ltd. (7780) Stock Forecast 2026 $185.00 — Price, Financials & Analyst Targets | Alpha Lenz